Your browser is no longer supported. Please, upgrade your browser.
Cardiovascular Systems, Inc.
Index- P/E- EPS (ttm)-0.34 Insider Own3.10% Shs Outstand38.93M Perf Week-6.62%
Market Cap1.35B Forward P/E752.67 EPS next Y0.04 Insider Trans0.37% Shs Float38.74M Perf Month-6.41%
Income-13.40M PEG- EPS next Q-0.09 Inst Own97.70% Short Float4.05% Perf Quarter-22.62%
Sales259.00M P/S5.21 EPS this Y56.50% Inst Trans1.03% Short Ratio6.83 Perf Half Y-13.33%
Book/sh6.96 P/B4.87 EPS next Y125.00% ROA-3.90% Target Price45.88 Perf Year-5.18%
Cash/sh5.20 P/C6.52 EPS next 5Y- ROE-5.00% 52W Range32.52 - 48.28 Perf YTD-22.60%
Dividend- P/FCF- EPS past 5Y27.50% ROI-4.20% 52W High-29.85% Beta0.85
Dividend %- Quick Ratio4.60 Sales past 5Y7.80% Gross Margin76.40% 52W Low4.15% ATR1.10
Employees780 Current Ratio5.20 Sales Q/Q67.10% Oper. Margin-4.60% RSI (14)34.92 Volatility3.72% 2.95%
OptionableYes Debt/Eq0.08 EPS Q/Q68.70% Profit Margin-5.20% Rel Volume0.79 Prev Close34.11
ShortableYes LT Debt/Eq0.08 EarningsAug 04 AMC Payout- Avg Volume229.57K Price33.87
Recom2.30 SMA20-5.00% SMA50-8.34% SMA200-15.11% Volume181,960 Change-0.70%
May-25-21Initiated Barclays Equal Weight $43
Nov-05-20Reiterated Needham Buy $44 → $47
Jul-22-20Initiated Northland Capital Outperform $40
Jul-17-20Initiated Barclays Overweight
Jun-11-20Upgrade Needham Hold → Buy
Apr-07-20Initiated Oppenheimer Outperform $47
Oct-18-19Initiated Guggenheim Buy
Apr-11-19Downgrade BofA/Merrill Buy → Underperform $51 → $42
Aug-22-18Initiated Stifel Buy $45
Jun-27-18Upgrade BofA/Merrill Underperform → Buy
Dec-15-17Downgrade Needham Buy → Hold
Oct-26-17Reiterated Needham Buy $37 → $36
Sep-22-17Initiated Raymond James Mkt Perform
Jun-21-17Downgrade BofA/Merrill Neutral → Underperform
Jan-30-17Initiated Lake Street Buy $40
Jan-26-17Reiterated Needham Buy $27 → $32
Oct-07-16Resumed JMP Securities Mkt Outperform
Aug-22-16Upgrade Leerink Partners Mkt Perform → Outperform
Aug-04-16Upgrade BofA/Merrill Underperform → Neutral
Aug-04-16Reiterated Needham Buy $23 → $27
Sep-22-21 09:10AM  
Sep-20-21 11:30AM  
Sep-11-21 08:54AM  
Sep-03-21 11:31AM  
Aug-31-21 09:57AM  
Aug-30-21 04:05PM  
Aug-06-21 02:39AM  
Aug-05-21 08:41AM  
Aug-04-21 11:31PM  
Jul-30-21 10:36AM  
Jul-28-21 03:03PM  
Jul-27-21 07:00AM  
Jul-15-21 02:48PM  
Jul-14-21 07:00AM  
Jun-23-21 02:43AM  
Jun-02-21 07:00AM  
Jun-01-21 07:00AM  
May-21-21 10:04AM  
May-20-21 04:00AM  
May-18-21 02:38AM  
May-11-21 10:59AM  
May-06-21 07:31PM  
May-03-21 04:05PM  
Apr-27-21 07:00AM  
Apr-15-21 07:00PM  
Apr-09-21 08:25AM  
Apr-08-21 07:00AM  
Apr-05-21 03:10AM  
Mar-24-21 07:00AM  
Mar-23-21 07:56AM  
Mar-22-21 09:00AM  
Mar-18-21 07:27AM  
Mar-17-21 07:00AM  
Mar-05-21 11:30AM  
Feb-14-21 01:32PM  
Feb-11-21 07:00AM  
Feb-09-21 09:56AM  
Feb-08-21 04:05PM  
Feb-04-21 01:34PM  
Feb-03-21 10:30PM  
Feb-02-21 10:22AM  
Feb-01-21 07:00AM  
Jan-27-21 05:00PM  
Jan-19-21 09:00AM  
Jan-18-21 04:05PM  
Jan-13-21 07:00AM  
Jan-04-21 04:05PM  
Dec-18-20 08:28PM  
Dec-04-20 11:31AM  
Nov-11-20 07:00AM  
Nov-06-20 08:46AM  
Nov-04-20 08:31PM  
Nov-03-20 10:08AM  
Oct-28-20 12:32PM  
Oct-21-20 07:00AM  
Oct-14-20 08:00AM  
Oct-12-20 01:00PM  
Oct-07-20 07:00AM  
Sep-15-20 10:01AM  
Sep-03-20 11:31AM  
Aug-20-20 04:05PM  
Aug-19-20 11:38AM  
Aug-17-20 02:55AM  
Aug-06-20 10:43AM  
Aug-05-20 01:31AM  
Aug-04-20 06:45PM  
Aug-03-20 12:48PM  
Jul-28-20 12:33PM  
Jul-27-20 04:05PM  
Jul-22-20 09:35AM  
Jul-14-20 07:00AM  
Jul-09-20 05:23PM  
Jul-05-20 05:05PM  
Jun-18-20 08:40AM  
Jun-11-20 04:05PM  
Jun-10-20 01:25PM  
Jun-09-20 10:32PM  
May-28-20 05:06AM  
May-06-20 10:44AM  
May-05-20 06:45PM  
Cardiovascular Systems, Inc., a medical device company, develops and commercializes solutions to treat peripheral and coronary artery diseases in the United States and internationally. The company offers peripheral artery disease products, which are catheter-based platforms to treat various plaque types in above and below the knee, including calcified plaque, as well as address various limitations related with surgical, catheter, and pharmacological treatment alternatives; and peripheral support products. It also provides Diamondback 360 Coronary orbital atherectomy systems (OAS), a coronary artery disease (CAD) product designed to facilitate stent delivery in patients with CAD who are acceptable candidates for percutaneous transluminal coronary angioplasty or stenting due to severely calcified coronary artery lesions. The company has a partnership with Chansu Vascular Technologies, LLC to develop peripheral and coronary everolimus drug-coated balloons. The company was formerly known as Shturman Cardiology Systems, Inc. and changed its name to Cardiovascular Systems, Inc. in January 2003. Cardiovascular Systems, Inc. was founded in 1989 and is headquartered in Saint Paul, Minnesota.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Aronson Martha GoldbergDirectorMay 10Buy34.591,50051,8857,500May 11 08:04 AM
Robb Rhonda J.Chief Operating OfficerMay 10Buy34.671,00034,670146,044May 11 08:02 AM
Ward Scott R.Chairman and CEOMay 10Buy34.411,00034,410507,815May 11 08:03 AM
Points Jeffrey S.Chief Financial OfficerMay 10Buy34.201,00034,20082,177May 11 08:02 AM